Early Results Of Verastem's VS-7375 In Pancreatic Cancer, Or How To Read A Reduction In CA19-9

Verastem reported a greater than 50% reduction of CA19-9 in 13 of 14 pretreated patients with metastatic pancreatic cancer treated with 900 mg of its oral KRAS G12D inhibitor VS-7375. Whether CA19-9 reliably tracks tumor burden and can predict survival is another question.